Yang H, Zhou Z, Lin L, et al. - Researchers determined the prevalence of the oncogenic driver MET exon 14 ( MET-ex14) among Chinese patients with various stages of lung cancer. For this purpose, they performed a retrospective analysis of genomic profiles of 11,306 Chinese patients. They also analyzed survival outcomes of patients who were treated with front-line crizotinib (n = 44) or chemotherapy (n = 14) who eligible for evaluation. The prevalence of For MET-ex14 alterations in this population was 1.1 %. Longer progression-free survival (PFS) was seen with crizotinib vs chemotherapy in evaluable patients with MET-ex14 alterations. In MET splice-site variants or in the presence of concurrent TP53 alterations, no significant difference in PFS or overall survival (OS) was identified. A shorter PFS but a similar OS resulted from concurrent MET amplification. A new MET Y1003C mutation was identified and showed a clinical response to crizotinib. These study results enhance the knowledge base about how molecular factors are related to clinical results of patients with MET exon 14 alterations.